eases such as IBD. Practical and ethical issues of PBSC transplantation in this setting have been discussed in a recent article. 5 A substantial but temporary benefit was obtained for our patient and probably, as Musso suggests, better outcome rates with less toxicity may be reached with more immunoablative regimens, such as those given for lymphomas and leukaemia. We feel that any evaluation of stem cell transplantation in IBD should assess the benefit of these periods of clinical remission with consequent improvement of quality of life for patients refractory to conventional therapy. Although much of the early stem cell transplantation for autoimmune diseases involved purging T lymphocytes from the graft, the current data on 145 patients in the autoimmune transplant programme does not support any advantage of such manipulation for the prevention of early relapse. 2 The immunological recovery pattern with an early CD19 and NK cell recovery, a prolonged CD4 and CD4/CD8 ratio reduction after high-dose chemotherapy has already been reported. Several authors relate this low number of CD4 cells to a persistently low level of naive CD4 + CD45RA + cells (thymus-dependent) related to thymic damage after high-dose chemotherapy. While studies in patients with established Crohn's disease have generally supported the predominance of cell-mediated immunity due to T helper 1 responses, enhanced humoral immunity appears to predominate in UC. An altered distribution of the serum immunoglobulin classes and IgG subclasses, especially in cases of active untreated IBD has been found frequently. In UC, intestinal B lymphocytes secrete increased amounts of IgG 1 compared to healthy subjects and this is reflected in the serum concentrations of total IgG and IgG subclasses. 6 Despite normal numbers of circulating lymphocytes 12 months after PBSC transplantation, deficiencies in humoral responsiveness contributed to a prolonged clinical remission of UC in our case. As normal IgG levels were reached after disease relapse, total serum IgG seemed to reflect the activity of the autoimmune disorder.
Unrelated cord blood transplantion in a Fanconi anemia patient using fludarabinebased conditioning
Fanconi anemia (FA) is a rare autosomal recessive disorder characterized by progressive pancytopenia, congenital malformations, chromosomal instability and predisposition to the development of malignancies. Hematopoietic cell transplantation (HCT) from a matched sibling donor is the only curative approach for the hematological abnormalities associated with FA; unfortunately only 25% to 35% of FA patients have a compatible cord blood or marrow donor. 1 Successful outcome for transplantation in FA patients with non-matched sibling donors is in the range of 25-40%; graft rejection, high risk of developing graft-versus-host disease (GVHD) and regimen-related toxicities have been This finding is supported by a recent report suggesting that serum IgG levels could be used as additional disease markers for activity in UC. 7 We feel that further investigations should be carried out to determine the significance of the correlation between IgG subclasses and IBD activity.
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Oncologia Umbilical-cord blood from unrelated donors can restore and sustain hematopoietic function, with a low risk of GVHD.
3 Studies performed at FHCRC showed that sublethal doses of total body irradiation (TBI, 200 cGy) followed by potent post-transplant immunosuppression (cyclosporin A, CsA plus mycophenolate mofetil, MMF) were able to prevent GVHD and graft rejection, allowing stable mixed chimerism. Fludarabine (FLU)-based conditioning regimens, capable of intense T cell immunosuppression, have been used successfully for various non-malignant diseases, with minimal toxicity and stable and durable engraftment. 4, 5 FA patients are natural candidates for non-myeloablative transplantation, because of their cellular hypersensitivity to DNA cross-linking agents, such as cyclophosphamide (CFA) and radiotherapy. 6 Considering all these studies, we decided that transplan-tation using unrelated cord blood, a non-myeloablative conditioning regimen and intense immunosuppression post transplant were appropriate for a patient with FA.
A 5-year-old girl with FA determined by DEB fragility and life-threatening marrow failure was referred to our center. She had no compatible related donor, but an HLA-A, B and DRB1 identical unrelated cord-blood had been
+ cells) were infused on day zero. GVHD prophylaxis was CsA (1.5 mg/kg/day i.v. from day −3 to day zero, then p.o. from day +1 to +100, tapering off on day +177) and MMF (30 mg/kg/day p.o. from day zero to day +40, tapering off on day +96). The regimen was well tolerated; mucositis, hemorrhagic cystitis and acute GVHD were not observed. She received 13 related single-donor platelet transfusions during her admission. The lowest granulocyte count was observed on day +6, and the first evidence of WBC engraftment was on day +16. Discharge occurred on day +23. On day +232, her Karnofsky score was 100%. Details of peripheral blood counts and engraftment are given in Table 1 .
Hematopoietic stem cell transplantation, from related marrow or umbilical cord blood, is considered the best therapy for FA patients. However, their exquisite hypersensitivity to conditioning agents, with well-known toxic effects (severe mucositis, gastrointestinal lesions and hemorrhage, fluid retention, cardiac failures and hemorrhagic cystitis) has been an obstacle. 7 In our experience, decreasing the doses of CFA without irradiation has resulted in lower rates of toxicity and acute and chronic GVHD, with good engraftment.
8-10 However, we have been limited to the setting of related transplantation.
Results of transplants from donors other than HLA-identical siblings are poor. The EBMTR reported 76 FA patients transplanted with marrow from unrelated donors. Primary graft failure was observed in 11 patients, and despite the use of CsA and methotrexate ± prednisone, approximately 55% developed grade II to IV acute GVHD. The overall Bone Marrow Transplantation event-free survival was 23%. 11 MacMillan et al 12 also reported the results of 29 patients with FA receiving transplants from alternate donors, and the probability of survival of the entire group at 1 year was 34%. Our own experience transplanting five patients with unrelated marrow is dismal, all five having died secondary to GVHD and infection.
Cord blood transplants from unrelated donors characteristically lead to good engraftment (approximately 80% of patients) and reduced severity of acute and chronic GVHD (23% and 25%, respectively). However, in FA patients poor engraftment secondary to host factors has been reported. 3 The group from FHCRC, together with collaborators at the University of Leipzig, Germany, demonstrated the feasibility of inducing mixed chimerism in unrelated transplants, utilizing FLU and sublethal irradiation as conditioning, and CsA and MMF post-transplant. FLU is a purine analogue that induces severe T cell immunosuppression, inhibiting DNA replication and repair. It may function as a radiosensitizer and has been used successfully as conditioning for non-myeloablative transplants. 5, 13 These results led the FHCRC group to design a new protocol for FA patients with unrelated donor stem cell transplantation. We used the same program (FLU and sublethal irradiation, associated with CsA and MMF post-transplant) to treat our patient, but gave unrelated cord blood. The patient had minimal complications during the transplant period, with no acute or chronic GVHD, and engraftment occurred gradually (Table 1) . Auerbach et al 14 published the data from a joint study with our group, demonstrating that 62% of our patients belong to the FA-A complementation group, and there is a trend suggesting that most FA patients in Brazil have a better prognosis. This fact may explain the favorable transplant response of our patient. However, Aker et al 13 reported a FA patient who was transplanted after conditioning with a FLU-based protocol, who also had minimal transplant-related toxicity.
The ideal conditioning regimen and post transplant immunosuppression for FA patients are yet to be determined. Efforts must be directed towards tailored regimens, based on patient sensitivity and donor compatibility.
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Pulmonary embolism after local urokinase instillation in a Hickman catheter
Local instillation of fibrinolytic agents is a method widely used for restoring permeability of malfunctioning central catheters. We present the case of a documented episode of subsegmental pulmonary embolism complicating this procedure.
A 45-year-old woman with metastatic breast cancer was mobilized to collect progenitor cells for autografting. A subclavian 13.5 Fr bilumen Hickman catheter had been implanted 4 months before and used for the administration of five courses of chemotherapy, without complications. The first apheresis was interrupted by repeated inlet line pressure alarms. The next day, fluoroscopic examination confirmed correct positioning of the catheter and detected no mechanical or thrombotic occlusion, but the second apheresis was likewise problematic. After the apheresis, each lumen was flushed with 10 000 IU of urokinase, according to the institutional protocol. The seal was maintained overnight. The next morning blood could not be drawn into a syringe, but there was no difficulty with infusion. No visible clot could be aspirated. Both lumeni were flushed with 10 ml of saline. Immediately after this, the patient experienced sudden pleuritic pain, dyspnoea and dry cough. Physical examination was unremarkable. Blood pressure was 90/50 mmHg and pulse 120. All the symptoms disappeared within minutes. Blood gases were normal and the haemodynamic condition remained stable. A 99mTc perfusion lung scan performed 30 min later revealed two small subsegmentary wedge-shaped defects on the anterior segment of the upper lobe and the anterobasal segment of the inferior lobe of the left lung. Ventilation examination was normal (Figures 1 and 2 ). Doppler ultrasound of the axillary, subclavian and jugular areas was normal. The patient received full anticoagulant therapy. Four weeks later, a CT scan showed no evidence of
